Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

2nd Annual Vaccine Manufacturing Conference

Pre-filled Syringes Americas Conference

Cell-Based Assays for Drug Discovery

6th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production

New Products

Competitor Analysis: Biologic and Immune Therapy of S. aureus Infections

Glaucoma and Retinopathies

Oncology Market Leaders Analyses and Outlook 2010-2025

World Ophthalmic Pharmaceutical Market 2010-2025

World Smoking-Cessation Drug Market 2010-2025

What's Next in Vaccines? HIV, Malaria, MRSA, and 30 Other Vaccine Targets in the 2010-2016 Pipeline

Lab Automation Markets, 2nd Edition (Systems, Key Companies, Forecasts and Trends)

Kinase Therapeutics: Pipeline Assessment and Commercial Prospects - Overview

5th Annual Pharmaceutical Anti-Counterfeiting Strategies

Amorphous Pharmaceutical Materials

BioPortfolio | Datamonitor Healthcare Reports | Monoclonal Antibodies Report: 2008 Update

Monoclonal Antibodies Report: 2008 Update

The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2013 and assessing trends by product, company, therapy area, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.

Scope

*Comprehensive financial strategic analysis of the mAb market out to 2013

*Global sales forecasts to 2013 for marketed and Phase III mAb products

*Analysis of market trends by product, company, therapy area, technology and target type

*Analysis of characteristics of key products and insight into direction of mAb technology evolution and pipeline dynamics

Highlights

The overall prescription pharmaceutical market is expected to face a decline in sales over 2011 to 2012 as a result of the 'patent cliff'. The patent cliff will impact the small molecule market, in contrast, the mAb market segment will continue to record robust growth.

Over the forecast period monoclonal antibodies are predicted to enjoy double-digit growth while small molecule drugs face declining growth rates. The main barrier to sales growth for small molecules is exposure to material generic competition, which will have no effect on mAbs out to 2013.

mAbs currently command a three-fold average revenue per product premium over small molecules. Positive factors supporting this premium include a higher demand due to addressing therapy areas of high unmet need and lower competitive intensity due to accessing novel target space.

Reasons to Purchase

*Assess the key products that will drive sales growth in the mAb market to 2013

*Understand the challenges and barriers to entry for new players seeking to venture into the mAb market

*Understand the nature of the generic threat across different molecule types and the insulation of mAb products from biosimilars

06-Jun-08 Format: PDF & SlidePack & DataPack Pages: 363

Table of Contents
Price: $7,600.00 / €5,467.44

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions